ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Recurrence"

  • 2017 American Transplant Congress

    A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium.

    V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.

    UCLA, LA

    Objective: While adoption of the Milan Criteria (MC) has improved outcomes following liver transplantation (LT) for hepatocellular carcinoma (HCC), recurrence remains a significant challenge. We…
  • 2017 American Transplant Congress

    Eculizumab Treatment on GC3 Recurrence on Renal Graft.

    G. Jeantet,1 D. Bertrand,3 A. Lionet,2 D. Anglicheau,4 V. Fremeaux-Bacchi,5 M. Le Quintrec.1

    1Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; 2Department of Nephrology, Dialysis and Transplantation, Lille, France; 3Department of Nephrology, Dialysis and Renal Transplantation, Rouen, France; 4Transplantation Rénale, Necker Hospital, Paris, France; 5Immunology, Hopital Européen Georges Pompidou, Paris, France

    Clinical C3G recurrence occured in more than 50% after renal transplantation and is the first cause of allograft loss at 5 years post-transplantation. Eculizumab (EC)…
  • 2017 American Transplant Congress

    Is Peri-Transplant Plasmapheresis Effective in the Prevention of Recurrence of FSGS?

    P. Verghese, M. Rheault, S. Chinnakotla, S. Jackson, A. Matas, B. Chavers.

    University of Minnesota, Minneapolis

    Many pediatric centers utilize a variety of protocols including scheduled plasmapheresis to prevent the dreaded recurrence of focal segmental glomerulosclerosis (FSGS) post-transplant. But the effectiveness…
  • 2017 American Transplant Congress

    Renal Transplant Outcomes in Primary FSGS Compared with Other Recipients: A National Review of the Irish Transplant Registry.

    S. Cormican,1 C. Kennedy,1,2 P. O'Kelly,1 B. Doyle,3 A. Dorman,3 P. Conlon.1,2

    1Nephrology, Beaumont Hospital, Dublin, Ireland; 2Medicine, Royal College of Surgeons, Dublin, Ireland; 3Pathology, Beaumont Hospital, Dublin, Ireland

    Primary focal segmental glomerular sclerosis (p-FSGS) raises specific peri-transplant concerns, one of which is disease recurrence (r-FSGS). We aimed to compare transplant outcomes in patients…
  • 2017 American Transplant Congress

    Hepatitis B Virus Infection Is Associated with Recurrent Nephropathy After Kidney Transplantation.

    G. Chen, C. Wang, Z. Wu, C. Wang, J. Qiu, L. Chen.

    Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Background Hepatitis B virus(HBV) infection can cause HBV associated nephropathy, and is one of the major reasons for secondary nephropathy. We carried out a retrospective…
  • 2017 American Transplant Congress

    Long-Term Outcomes of Kidney Transplant Recipients with Primary Idiopathic Focal Segmental Glomerulosclerosis (FSGS).

    D. Khadzhynov, F. Halleck, L. Lehner, E. Schrezenmeier, K. Budde, O. Staeck.

    Nephrology, Charité Universitaetsmedizin, Berlin, Germany

    Introduction:Few data exists analyzing recurrence rates, treatment response and long-term outcomes in kidney transplant recipients (KTR) with primary FSGS.Methods: This retrospective observational study included 1218…
  • 2016 American Transplant Congress

    Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.

    D. Kim, G. Na, T. Hong, Y. You.

    Surgery, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.

    Purpose: For living-donor liver transplantation (LDLT), there has been a tendency to accept extended criteria in comparison with deceased-donor liver transplantation (DDLT). However, HCC recurrence…
  • 2016 American Transplant Congress

    Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.

    M. Grąt,1 J. Stypułkowski,1 W. Patkowski,1 K. Wronka,1 M. Wasilewicz,2 K. Grąt,3 L. Masior,1 M. Krasnodębski,1 Z. Lewandowski,4 M. Krawczyk.1

    1Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; 2Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland; 3Second Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland; 4Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland.

    Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…
  • 2016 American Transplant Congress

    Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?

    S. Song, J. Lee, S.-K. Kwon, J. Lee, J. Lee, D. Han, G. Choi, M. Kim, J. Choi, S. Kim, D. Joo.

    Department of Surgery and The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea.

    Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not…
  • 2016 American Transplant Congress

    Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation.

    C. Cho, K. Kim, S. Kim, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, N. Lee.

    Surgery, Samsung Medical Center, Seoul, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

    Background Predicting risk for recurrence of hepatocellular carcinoma (HCC) following living donor liver transplantation (LDLT) is clinically important.Methods We performed a retrospective study for assessment…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences